Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients

References

• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al.; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Harrington DP, Anderson JR. International non-Hodgkin's lymphoma prognostic factors project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
   PubMed Web of Science ®Google Scholar
• Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012;119:4619–4624.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, et al. Novel disease targets and management approaches for diffuse large B-cell lymphoma. Leuk Lymphoma 2010;51(Suppl. 1):1–10.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL rituximab-CHOP consortium program. Blood 2013;121:4021–4031; quiz 4250.
   PubMed Web of Science ®Google Scholar
• Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007;110:29–36.
   PubMed Web of Science ®Google Scholar
• Liedtke M, Hamlin PA, Moskowitz CH, et al. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006;17:909–913.
   PubMed Web of Science ®Google Scholar
• Thompson CA, Maurer MJ, Ghesquieres H. Utility of post-therapy surveillance scans in DLBCL. Presented at the American Society of Clinical Oncology Conference, 30 May–3 June 2013, Chicago, IL, USA.
   Google Scholar
• Armitage JO, Loberiza FR. Is there a place for routine imaging for patients in complete remission from aggressive lymphoma?Ann Oncol 2006;17:883–884.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al.; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989–1996.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Mounier N, Canals C, Gisselbrecht C, et al.; the Lymphoma Working Party of the European Blood and Marrow Transplantation Registry (EBMT). High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the european blood and marrow transplantation registry. Biol Blood Marrow Transplant 2012;18:788–793.
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Putten WL, van't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial. Blood 2008;111:537–543.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de L'adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011;29:4079–4087.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012;30:4462–4469.
   PubMed Web of Science ®Google Scholar
• El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007;18:1363–1368.
   PubMed Web of Science ®Google Scholar
• Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004;101:1835–1842.
   PubMed Web of Science ®Google Scholar
• Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the parma trial. J Clin Oncol 1998;16:3264–3269.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Rambaldi A, Rossi A, et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haematol 2001;114:333–341.
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493–1498.
   PubMed Web of Science ®Google Scholar
• Filmont JE, Gisselbrecht C, Cuenca X, et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007;110: 1361–136s9.
   PubMed Web of Science ®Google Scholar
• Dickinson M, Hoyt R, Roberts AW, et al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol 2010;150:39–45.
   PubMed Web of Science ®Google Scholar
• Roland V, Bodet-Milin C, Moreau A, et al. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. Bone Marrow Transplant 2011;46:393–399.
   PubMed Web of Science ®Google Scholar
• Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist 2010;15:750–759.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Zhang MJ, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010;16:35–45.
   PubMed Web of Science ®Google Scholar
• Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011;17:18–19.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Chalhoub B, Suzan F, et al. Outcome of elderly patients with aggressive non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure. Leuk Lymphoma 2004;45:1391–1394.
   PubMed Web of Science ®Google Scholar
• Vose JM, Zhang MJ, Rowlings PA, et al.; Autologous Blood and Marrow Transplant Registry Lymphoma Working Committee. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 2001;19:406–413.
   PubMed Web of Science ®Google Scholar
• Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002;20:2344–2352.
   PubMed Web of Science ®Google Scholar
• Siena S, Bregni M, Brando B, et al. Circulation of CD34 + hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989;74:1905–1914.
   PubMed Web of Science ®Google Scholar
• Copelan EA, Ceselski SK, Ezzone SA, et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997;15:759–765.
   PubMed Web of Science ®Google Scholar
• Siena S, Schiavo R, Pedrazzoli P, et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;18:1360–1377.
   PubMed Web of Science ®Google Scholar
• Bolwell BJ, Pohlman B, Rybicki L, et al. Patients mobilizing large numbers of CD34 + cells (“super mobilizers”) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2007;40:437–441.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, et al.; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767–4773.
   PubMed Web of Science ®Google Scholar
• Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010;45:39–47.
   PubMed Web of Science ®Google Scholar
• Berz D, McCormack EM, Winer ES, et al. Cryopreservation of hematopoietic stem cells. Am J Hematol 2007;82:463–472.
   PubMed Web of Science ®Google Scholar
• Blystad AK, Delabie J, Kvaloy S, et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004;125:605–612.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stem- cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005;23:2240–2247.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Avivi I, Rowe JM, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012;118:4706–4714.
   PubMed Web of Science ®Google Scholar
• Vose JM, Carter S, Burns LJ, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 2013;31:1662–1668.
   PubMed Web of Science ®Google Scholar
• Hill BT, Rybicki L, Bolwell BJ, et al. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. Br J Haematol 2011;152:561–569.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the bone marrow transplant survivor study. Blood 2005;105:4215–4222.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Ness KK, Burns LJ, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant 2007;13:1153–1159.
   PubMed Web of Science ®Google Scholar
• Freytes CO, Loberiza FR, Rizzo JD, et al.; Lymphoma Working Committee of the International Bone Marrow Transplant Registry. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004;104:3797–3803.
   PubMed Web of Science ®Google Scholar
• Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 1997;20:369–374.
   PubMed Web of Science ®Google Scholar
• van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011;29:1342–1348.
   PubMed Web of Science ®Google Scholar
• Nagler A, Slavin S, Varadi G, et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000;25:1021–1028.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Goldstone AH, Mackinnon S, et al.; Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the lymphoma working party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310–4316.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927–1932.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22:1622–1627.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011;11:462–466.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341–347.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Gerecitano JF, Goy A, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood 2012;120(Suppl. 1): Abstract 686.
   Google Scholar